% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • dooper55 dooper55 Nov 29, 2012 8:09 AM Flag

    New hire for OMS302 sales

    SEATTLE, Nov. 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the appointment of Thomas A. Mitro as vice president, sales and marketing.

    Mr. Mitro has over 30 years of experience in the pharmaceutical industry, spanning sales and marketing as well as business development. Prior to joining Omeros, Mr. Mitro served from 2002 until 2012 as vice president, sales and marketing at ISTA Pharmaceuticals, Inc. where he oversaw the building of ISTA's commercial infrastructure and launch of five eye care products. When ISTA was acquired by Bausch & Lomb in June of 2012, ISTA was the third largest branded prescription eye care business in the United States. Before ISTA, Mr. Mitro served for over 20 years in various positions with Allergan, Inc., including vice president, skin care; vice president, business development; and vice president, e-business. Mr. Mitro received his #$%$. from Miami University.

    "I am excited to join Omeros' impressive management team and to help advance the Company's products to market, starting with OMS302 for lens replacement surgery," stated Mr. Mitro. "With two successful Phase 3 clinical trials, Omeros has a variety of options to commercialize OMS302, including going alone, partnering and co-promoting. I believe that OMS302 will be widely used by ophthalmologists with the potential to generate significant revenues, and I look forward to contributing to its commercial success."

    "We are very pleased to have Tom join Omeros as we prepare to launch OMS302," said Gregory A. Demopulos, M.D., Omeros' chairman and chief executive officer. "We are building an efficient commercialization strategy that can be targeted and levered to maximize success. Tom's years of experience in eye care - building industry-leading ophthalmic franchises - will be valuable to us as we refine and execute our strategy to deliver on OMS302's market potential."

8.52+0.51(+6.37%)Oct 21 4:00 PMEDT